预约演示

Daewoong and CSP sign licence deal for IPF therapy in Greater China region

2023-01-31

孤儿药引进/卖出快速通道临床2期

Daewoong Pharmaceutical and CS Pharmaceuticals sign a licensing agreement for Bersiporocin. Credit: Daewoong Pharmaceutical Co., Ltd. / PRNewswire.

Daewoong Pharmaceutical has CS Pharmaceuticalsve licensing agreement with CS PBersiporocinls (CSP) fDaewoong Pharmaceutical Co., Ltd. PRS inhibitor, in the Greater China region for Idiopathic Pulmonary Fibrosis (IPF).

Daewoong Pharmaceuticall have exclusive rights for the development and marCS Pharmaceuticalsocin to treBersiporocinll as other respiratory indications in the region, including mainlIdiopathic Pulmonary Fibrosis (IPF)iwan.

As per the termsCSP the agreement, Daewoong will receive a total consideration of upBersiporocinncluding uIPFont and development milestone payments of up to $76m, along with royalties on net sales.

Being developed by Daewoong, BersipDaewoongas already received FastTrack Designation and Orphan Drug Designation from the US Food and Drug Administration (FDA) to treat IPF.

Last year, the company commenBersiporocinregional Phase II clinical trial of Bersiporocin for IPF treatment, with results expFood and Drug Administration (FDA)ar.IPF

The Korea Drug Development Fund is supporting the trial by providing funds.Bersiporocin IPF

CSP Korea Drug Development Fundcuring the Chinese commercial rights to Bersiporocin with the initial focus in IPF marks another milestone for CSP, as we continue to expand our portfolio of innovative products in China.

CSPF is a priority rare disease in China, which marks a huge unmet needBersiporocinently estimated that nearlyIPF% of IPF patients in China wiCSPdie within two to three years after diagnosis.

“IPFpleting this transaction further strengthens our rare disease portfolio as we continue to focus on bringing innovaIPFe rare disease and ophthalmology medicines to Chinese patients, to address the significant unmet medical needs in this rapidly growing market.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构